Welcome to Prospect - a support group for prostate cancer patients, their wives, partners and carers.
Prospect is run by prostate cancer survivors for the benefit of the communities in Bristol and surrounding districts

  • Hear about exciting trial results

    At our next members’ meeting on October 12 we will hear about the STAMPEDE trial from Dr Serena Hilman, Consultant Clinical Oncologist and Research and Development Director at Weston Hospital. The trial’s exciting “potentially game-changing” results could trigger a big change in advanced prostate cancer treatment. It is the largest prostate cancer clinical trial, designed to test the effect of giving different treatments earlier. Our meeting at the BAWA, Filton, starts at 7.30pm.

  • New info for Black men

    One in 4 Black men will get prostate cancer at some point. That’s double the overall one in 8 risk faced by all UK men. Prostate Cancer UK’s updated leaflet has all the information you need to know if you’re at risk: See

  • New cancer test on way

    A ÂŁ10 urine test for prostate cancer which not only picks up the disease but also reveals the size of tumours so that doctors know whether to operate could be available within 18 months, the Daily Telegraph reported in September. See

  • Xofigo® drug withdrawn

    As the Cancer Drugs Fund (CDF), set up to pay for new, expensive cancer drugs, is no longer affordable, NHS England has decided to stop funding radium-223 (Xofigo®) for new advanced prostate cancer patients. Men on the drug will not be affected. Abiraterone and enzalutamide will remain on the CDF. See report

  • Drug might stop cancer spread

    A single molecule has been identified that could be central to the mechanism of the spread of prostate cancer. The study, published in the journal Cancer Cell, was completed by researchers from the Thomas Jefferson University in Philadelphia, PA. The results offer a target for the development of a drug that could prevent metastasis in prostate cancer – and possibly other cancers, too.
    The researchers say they have discovered that a molecule called DNA-PKcs could give a means of knocking out major pathways that control cancer spread. A drug that inhibits DNA-PKcs is being tested in clinical trials. See

  • Five types of prostate cancer found

    New research published in July by researchers revealed that prostate cancer can be divided into five distinct groups, each with a unique molecular signature that appears to predict how well a patient will do after surgery. It was stressed there were still many questions to be ironed out. See

  • Space tool may detect prostate cancer

    An instrument of a type found on board Philae, the comet 67P lander, is being used in the search for a non-invasive detection of prostate cancer. The instrument is a gas chromatograph-mass spectrometer which sniffs and analyses the main chemical compounds that make up the comet.  The tool, developed by Open University scientists and Rutherford Appleton Laboratory, is being trialled in such projects as testing submarines’ air quality and in the fight against bed bugs  – Open Minds, the magazine for OU alumni


A friendly and supportive network that aims to:


We have found that knowledge is of great benefit to the patient. It enables him to play an active part in the decision-making process, for example in selecting the best treatment.

We offer a friendly welcome – come and join us

Are you just diagnosed, or do you suspect that you may have prostate cancer? Then for friendly peer support and an introduction to Prospect call or text our helpline on

07585 963535

This site has been compiled by prostate cancer survivors. We do not claim to have specialist knowledge other than that gained by prostate cancer patients during the course of their treatment.

We give illustrated talks 

Mike Broxton gives prostate cancer awareness talks to interested groups, including those with learning disabilities. To arrange for a talk, contact prospect.bristol@gmail.com or our helpline: 07585 963535.

New secretary volunteers

Chris Millett  volunteered to be our secretary after an appeal at the AGM. A successful year was reported and the committee was re-elected. An interesting talk was given by Pat Turton, Lead Lecturer for Cancer at the UWE.

Treatment difficulties

It can take years for a treatment to become available to patients who need it –  and even then, some are not considered cost-effective enough to be routinely available on the NHS. The government are reviewing how to speed up access to treatments on the NHS and they want patients’ input. Prostate Cancer UK thought this was a good opportunity to tell them some of the difficulties men have had in accessing treatments. If your clinician judged your circumstances to be exceptional, they might have lodged an Individual Funding Request to see if you could receive a treatment not available on the NHS. If you knew that this was the case for you and the application was unsuccessful, Prostate Cancer UK wanted to share your experience with government.  Although that exercise has now ended, Prostate Cancer UK still want to hear from any unsuccessful applications.

Bristol ‘breakthrough’

Bristol University scientists have made a breakthrough in treating prostate cancer. Injections have been tested on mice and could be tested on patients before long. Sebastian Oltean from the university gave us a talk on this in January.

  • Know your risk

    Prostate Cancer UK has a new infographic and booklets.

    Treatment help

    www.myprostate.eu is now also available in English and prostate cancer patients can exchange information and help each other with treatment decisions.

  • Buddies support

    A NEW emotional support service is being offered to people affected by cancer, called Macmillan Skype Buddy. To use it, you need Skype and an email account. The charity is also looking for volunteers to train as buddies.

  • Macmillan Bristol Buddies

    A new service to support adult cancer patients. It offers emotional and practical support in people’s homes for up to 12 weeks across Bristol. Ring 07543 248714 or email